A Survey on the Role of Interleukin-10 in Breast Cancer: A Narrative.

Interleukin (IL)-10, a multifunctional immune-regulatory cytokine with both immunosuppressive and anti-angiogenic functions, is produced by immune cells including macrophages, T lymphocytes, and natural killer cells. Among other effects, IL-10 promotes tumor cell proliferation and metastasis via immunosuppression. Interleukin-10-mediated immunosuppression is aided by synthesis of tumor necrosis factor, IL-1, IL-12, and chemokines, and down regulation of the surface co-stimulatory molecules CD80 and CD86 on tumors. Interleukin-10 also promotes IL-6 expression and synthesis, which causes cell proliferation via B cell lymphoma-2 (Bcl-2) upregulation and changes the proliferation/apoptosis equivalence toward neoplastic cell proliferation. Moreover, IL-10 inhibits tumorigenesis via down-regulation of VEGF, IL-1b, TNF-α, IL-6, and MMP-9. Interleukin-10 also inhibits nuclear factor-KB (NF-KB) translocation. Interleukin-10 has been reported to have both tumor-promoting and -inhibiting properties. It seems that IL-10 agonists and antagonists may have therapeutic effects via different mechanisms. Moreover, IL-10 gene polymorphisms may determine breast cancer susceptibility.

[1]  M. Sheikhha,et al.  CYP2D6 Genotype and Risk of Recurrence in Tamoxifen Treated Breast Cancer Patients. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[2]  R. Asadollahi,et al.  Interleukin-10 Promoter Polymorphisms and Breast Cancer Risk in Iranian Women , 2005 .

[3]  M. Lotze,et al.  Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. , 1996, Journal of immunology.

[4]  Jian Huang,et al.  Serum IL-10 Predicts Worse Outcome in Cancer Patients: A Meta-Analysis , 2015, PloS one.

[5]  S. Gangemi,et al.  Interleukin-12 and interleukin-10 production by mononuclear phagocytic cells from breast cancer patients. , 1999, Immunology letters.

[6]  M. Ricote,et al.  IL‐6, its receptors and its relationship with bcl‐2 and bax proteins in infiltrating and in situ human breast carcinoma , 2005, Histopathology.

[7]  M. Roncarolo,et al.  A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells. , 1999, Journal of immunology.

[8]  Y. Li,et al.  Relationship between IL-10 expression and prognosis in patients with primary breast cancer , 2014, Tumor Biology.

[9]  H. Weiner,et al.  A dominant function for interleukin 27 in generating interleukin 10–producing anti-inflammatory T cells , 2007, Nature Immunology.

[10]  T. Mcclanahan,et al.  TGF-β and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain TH-17 cell–mediated pathology , 2007, Nature Immunology.

[11]  Ozlem Keskin,et al.  The structural network of Interleukin-10 and its implications in inflammation and cancer , 2014, BMC Genomics.

[12]  Ryan L Brunsing,et al.  Induction of interleukin‐10 in the T helper type 17 effector population by the G protein coupled estrogen receptor (GPER) agonist G‐1 , 2011, Immunology.

[13]  Xing-lian Jiang,et al.  Macrophage-produced IL-10 limits the chemotherapy efficacy in breast cancer , 2015, Journal of Zhejiang University-SCIENCE B.

[14]  M. Howell.  Interleukin-10 Gene Polymorphisms and Cancer , 2013 .

[15]  M. Wojtukiewicz,et al.  Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. , 2003, Roczniki Akademii Medycznej w Bialymstoku.

[16]  R. Konwar,et al.  Role of interleukin-10 in breast cancer , 2012, Breast Cancer Research and Treatment.

[17]  M. Braga,et al.  Increased interleukin-10 serum levels in patients with solid tumours. , 1996, Cancer letters.

[18]  F. Finkelman,et al.  Anti-CD3 antibody induces rapid expression of cytokine genes in vivo. , 1990, Journal of immunology.

[19]  A. Bateman,et al.  Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. , 2004, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[20]  A. Sheikh,et al.  Elevated levels of serum alpha(2) macroglobulin in wild black bears during hibernation. , 2003, Biochimie.

[21]  M. Oft,et al.  Pegylated IL-10 induces cancer immunity: the surprising role of IL-10 as a potent inducer of IFN-γ-mediated CD8(+) T cell cytotoxicity. , 2013, BioEssays : news and reviews in molecular, cellular and developmental biology.

[22]  E. Kassi,et al.  Estrogen Receptor Signaling and Its Relationship to Cytokines in Systemic Lupus Erythematosus , 2010, Journal of biomedicine & biotechnology.

[23]  U. Langsenlehner,et al.  Association of interleukin-10 gene variation with breast cancer prognosis , 2010, Breast Cancer Research and Treatment.

[24]  R. Coffman,et al.  Interleukin-10 and the interleukin-10 receptor. , 2001, Annual review of immunology.

[25]  R. Konwar,et al.  Polymorphic variations in IL-1β, IL-6 and IL-10 genes, their circulating serum levels and breast cancer risk in Indian women. , 2012, Cytokine.

[26]  M. Lotze,et al.  Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ. , 2001, Blood.

[27]  Feng Gao,et al.  Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway , 2015, Medical Oncology.

[28]  G. Gerken,et al.  Increased Levels of Interleukin-10 in Serum from Patients with Hepatocellular Carcinoma Correlate with Profound Numerical Deficiencies and Immature Phenotype of Circulating Dendritic Cell Subsets , 2004, Clinical Cancer Research.

[29]  F. Marincola,et al.  The dual role of IL-10. , 2003, Trends in immunology.

[30]  R. Tamez-Guerra,et al.  Relationship between IL-10 and tumor markers in breast cancer patients. , 2006, Breast.

[31]  P. Drew,et al.  IL-10 and IL-12 expression in breast cancer patients and effect of therapy , 2008 .

[32]  R. Konwar,et al.  Breast cancer risk associated with polymorphisms of IL-1RN and IL-4 gene in Indian women. , 2009, Oncology research.

[33]  P. Aloy,et al.  Interactome3D: adding structural details to protein networks , 2013, Nature Methods.

[34]  J. Kim,et al.  IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. , 1995, Journal of immunology.

[35]  B. Paulweber,et al.  Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk , 2005, Breast Cancer Research and Treatment.

[36]  A. Tobar,et al.  Inhibition of Interleukin-10 by the Immunomodulator AS101 Reduces Mesangial Cell Proliferation in Experimental Mesangioproliferative Glomerulonephritis , 2004, Journal of Biological Chemistry.

[37]  Hue Lee,et al.  The role of interleukin-10 in the progression of human papillomavirus-associated lung carcinoma , 2013, Oncoimmunology.

[38]  Y. H. Lee,et al.  Inhibition of IL-10-induced STAT3 activation by 15-deoxy-Delta12,14-prostaglandin J2. , 2005, Rheumatology.

[39]  B. Bonavida,et al.  Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  K. Kliche,et al.  Elevated Serum Levels of IL-10 are Associated with Inferior Progression-Free Survival in Patients with Hodgkin's Disease Treated with Radiotherapy , 2004, Leukemia & lymphoma.

[41]  D. Laune,et al.  Oestrogen receptor negative breast cancers exhibit high cytokine content , 2007, Breast Cancer Research.

[42]  E. Venetsanakos,et al.  High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours. , 1997, British Journal of Cancer.

[43]  A. Cripps,et al.  GM‐CSF, IL‐1α, IL‐β, IL‐6, IL‐8, IL‐10, ICAM‐1 and VCAM‐1 gene expression and cytokine production in human duodenal fibroblasts stimulated with lipopolysaccharide, IL‐1α and TNF‐α , 1994, Clinical and experimental immunology.

[44]  B. Song,et al.  Association of interleukin-10 gene polymorphisms with breast cancer in a Chinese population , 2010, Journal of experimental & clinical cancer research : CR.

[45]  S. Durham,et al.  Grass Pollen Immunotherapy Induces an Allergen-Specific IgA2 Antibody Response Associated with Mucosal TGF-β Expression1 , 2007, The Journal of Immunology.

[46]  P. Ferrari,et al.  Cytokines in the management of high risk or advanced breast cancer: an update and expectation. , 2009, Current cancer drug targets.

[47]  T. Luger,et al.  Binding of IL-1 beta to alpha-macroglobulins and release by thioredoxin. , 1990, Journal of immunology.

[48]  K. Samoilova,et al.  Pro- and anti-inflammatory cytokine content in human peripheral blood after its transcutaneous (in vivo) and direct (in vitro) irradiation with polychromatic visible and infrared light. , 2006, Photomedicine and laser surgery.

[49]  M. Sabel,et al.  Immunologic approaches to breast cancer treatment. , 2005, Surgical oncology clinics of North America.

[50]  S. L. Gonias,et al.  Interleukin-4 and IL-10 bind covalently to activated human alpha2-macroglobulin by a mechanism that requires Cys949. , 2000, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[51]  P. Bruzzi,et al.  Association of breast cancer and polymorphisms of interleukin-10 and tumor necrosis factor-alpha genes. , 2003, Clinical chemistry.

[52]  W. Borth.  Alpha 2-macroglobulin. A multifunctional binding and targeting protein with possible roles in immunity and autoimmunity. , 1994, Annals of the New York Academy of Sciences.

[53]  P. Nallari,et al.  A Common SNP of IL-10 (-1082A/G) is Associated With Increased Risk of Premenopausal Breast Cancer in South Indian Women , 2015, Iranian journal of cancer prevention.